Gong Chen

Title: Gong Chen - Innovator in Engineered Immune Cell Technology

Introduction

Gong Chen is a prominent inventor based in Nanjing, China. He is currently associated with Bioheng Therapeutics Limited, where he focuses on groundbreaking research in the field of immunotherapy. Despite having no granted patents to his name, his contributions to the development of engineered immune cells are noteworthy.

Latest Patent Applications

Gong Chen has filed several significant patent applications, including:

1. **Engineered Immune Cell with CD7 Gene Knock-Out and Use Thereof** - This application discloses an engineered immune cell with a CD7 gene knock-out. The invention involves designing and synthesizing an sgRNA that specifically targets the CD7 gene, achieving high knock-out efficiency. This sgRNA can be utilized for preparing a CD7-targeting engineered immune cell, which can further be developed into a CD7-targeting universal CAR-T cell.

2. **Novel Chimeric Antigen Receptor and Use Thereof** - This application provides a chimeric antigen receptor that includes an antigen binding region, a transmembrane domain, and an intracellular signaling region. The antigen binding region specifically targets CD7, while the intracellular signaling region consists of a co-stimulatory domain, a primary signal transduction domain, and a γC chain or its intracellular region. The application also covers an engineered immune cell comprising this chimeric antigen receptor and its pharmaceutical composition for cancer treatment.

Conclusion

Gong Chen's innovative work in engineered immune cell technology highlights his commitment to advancing cancer treatment methodologies. His latest patent applications reflect his dedication to developing effective therapeutic solutions.